Results 41 to 50 of about 772 (113)

A Dose-Escalating Study With the Fetal Estrogen Estetrol in Healthy Men

open access: yes, 2018
Context Luteinizing hormone–releasing hormone (LHRH) agonists have replaced estrogens for endocrine treatment of advanced prostate cancer (PC) because of cardiovascular side effects.
Cornelis Kluft   +7 more
core   +1 more source

Aplicaciones y efectos del estetrol en la práctica ginecológica [PDF]

open access: yes
Este estudio abarca información sobre el estetrol (E4), el mismo que es un estrógeno endógeno sintetizado exclusivamente por el hígado fetal durante la gestación, alcanzando concentraciones significativas en la circulación materna a través del ...
Ariana Nicole Erazo Mesías   +3 more
core  

Estetrol, a newly designated orphan drug, for attenuation of neonatal Hypoxic-Ischemic Encephalopathy (HIE)

open access: yes, 2018
Estetrol, a newly designated orphan drug, for attenuation of neonatal Hypoxic-Ischemic Encephalopathy (HIE) Ekaterine Tskitishvili1*, Christel Pequeux1, Renaud Viellevoye2, Michelle Nisolle3, Agnes Noël1 and Jean-Michel Foidart1 1Laboratory of ...
Nisolle, Michelle   +5 more
core   +1 more source

Hypoxic-Ischemic Encephalopathy and Premature Babies Brain Damage: Impact of Estetrol

open access: yes, 2015
peer reviewedNeonatal hypoxic-ischemic brain injury remains a main problem of perinatal medicine. About 20% of affected newborns die in the postnatal period, and an additional 25% will sustain childhood disabilities mostly in the form of motor and ...
Nisolle, Michelle   +3 more
core  

Estetrol attenuates neonatal hypoxic–ischemic brain injury

open access: yes, 2014
peer reviewedEstetrol (E4) is a recently described natural estrogen with four hydroxyl-groups that is synthesized exclusively during pregnancy by the human fetal liver. It has important antioxidative activity.
Nisolle, Michelle   +6 more
core   +1 more source

Pro-Apoptotic Effects of Estetrol on Long-Term Estrogen-Deprived Breast Cancer Cells and at Low Doses on Hormone-Sensitive Cells

open access: yes, 2019
Purpose: Postmenopausal women with estrogen receptor-positive breast cancers often respond initially to tamoxifen or aromatase inhibitor therapy. Resistance to these treatments usually develops within 12 to 18 months.
Carole Verhoeven   +4 more
core   +1 more source

Estetrol/drospirenone for combined oral contraception: a systematic review of efficacy, cycle control, and safety [PDF]

open access: gold
Manuel Sánchez Prieto   +6 more
openalex   +1 more source

E4_paper_suppl_figs_xyz1348068aa41d3_(1) – Supplemental material for Pro-Apoptotic Effects of Estetrol on Long-Term Estrogen-Deprived Breast Cancer Cells and at Low Doses on Hormone-Sensitive Cells

open access: yes, 2019
Supplemental material, E4_paper_suppl_figs_xyz1348068aa41d3_(1) for Pro-Apoptotic Effects of Estetrol on Long-Term Estrogen-Deprived Breast Cancer Cells and at Low Doses on Hormone-Sensitive Cells by Wei Yue, Carole Verhoeven, Herjan Coelingh Bernnink ...
Herjan Coelingh Bernnink (6734495)   +4 more
core   +1 more source

Home - About - Disclaimer - Privacy